Assessing the safety of warfare nerve agents antidotes using dual-chamber plethysmography
Despites international treaties, the usage of chemical weapons is still a concern nowadays. This article highlights a study using Dual-chamber plethysmography for the determination of the NOAEL dose of an oxime, for the treatment of organophosphorus-nerve agents poisoning.
Evaluating large Animal models of Heart Failure with hFpEF using clinical scores
Learn about Heart Failure with Preserved Ejection Fraction and the development of large animal models for studying and testing therapies for this complex condition.
Rats for cardiovascular research
Because of the multifactorial nature of cardiovascular diseases, there is not a single specie which is optimal for all studies. The choice of an animal model should be carefully made as it can affect the experimental outcomes and the reasonable translation of study findings to humans.
Cancer and Chemotherapy-induced Cardiotoxicity
To develop safe and effective cancer therapies, it is crucial to understand chemotherapy-induced cardiotoxicity and cancer‐related cardiac complications. This blog highlights recent discoveries in this field.
Cell-based & cell-free therapies for myocardial infarction
After myocardial infarction, the heart fails to regenerate and ischemic/reperfusion injury leads to cardiomyocyte loss and fibrosis leading to impaired heart function. The medical treatment for heart failure, for the most part, is not disease modifying, it’s simply symptomatic. Another strategy is to address the fundamental issue of a failing heart, which is the loss of cardiomyocytes after a heart attack.
Maximizing Insights from Preclinical Safety Studies in the context of rising costs and shortages
During the 2023 Safety Pharmacology Society (SPS) Conference in Brussels, scientists from leading preclinical contract organizations (CROs) discussed how traditional IND-enabling studies involving primates and dogs can be complemented (and sometimes even replaced) by alternative models such as mice, rats, rabbits and pigs.
Integrating SEND outcomes
As an industry partner with deep expertise in IND-enabling studies, emka TECHNOLOGIES helps nonclinical scientists comply with SEND requirements by generating SEND 3.1 compatible tables directly from emka TECHNOLOGIES software.
